Health and Fitness Health and Fitness
Tue, December 13, 2011
[ Tue, Dec 13th 2011 ] - Market Wire
Healthways to Update 2011 Financial Guidance after Market Close on December 20
[ Tue, Dec 13th 2011 ] - Market Wire
Seattle Genetics and Millennium Report Data from .. Brentuximab Vedotin) in Front-line Hodgkin Lympho
[ Tue, Dec 13th 2011 ] - Market Wire
U.S. Physical Therapy to Present at the Oppenheimer 22nd Annual Healthcare Conference
[ Tue, Dec 13th 2011 ] - Market Wire
St. Jude Medical Announces First Implant in Europ .. Studying Portico Transcatheter Aortic Heart Valve
[ Tue, Dec 13th 2011 ] - Market Wire
Die Europische Kommission erteilt Astellas Pharma .. zulassung zur Verwendung von DIFICLIRa" in der EU
[ Tue, Dec 13th 2011 ] - Market Wire
La Comisin Europea concede la autorizacin de mark .. Astellas Pharma Europe Ltd., para su uso en la UE
[ Tue, Dec 13th 2011 ] - Market Wire
PhotoMedex and Radiancy Complete Merger
[ Tue, Dec 13th 2011 ] - Market Wire
Bio-Path Holdingsa Initial Phase I Data in Leukem .. s That Its Neutral Lipid Delivery Technology Anti
[ Tue, Dec 13th 2011 ] - Market Wire
Thera Maxa" Cold and Flu Debuts in Times Square D .. ring the Height of the 2011 / 2012 Holiday Season
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. uestcor Pharmaceuticals, Inc. and Perrigo Company
[ Tue, Dec 13th 2011 ] - Market Wire
Direction of Market Influences - Report Highlight .. ceutical Industries Ltd (ADR) and Sanofi SA (ADR)
[ Tue, Dec 13th 2011 ] - Market Wire
A Change in Tides - Featured Research on Tenet Healthcare Corporation and Deluxe Corporation
[ Tue, Dec 13th 2011 ] - Market Wire
A Potent and Safe Wound Care Agent
[ Tue, Dec 13th 2011 ] - Market Wire
GenVec President and Chief Executive Officer Announces Retirement
[ Tue, Dec 13th 2011 ] - Market Wire
Keryx Biopharmaceuticals Announces Phase 2 Data f .. e) in Hodgkin's Lymphoma Presented at ASH Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
New Clinical Study Presented at the NYPGA Meeting .. oring -- Considered the Fourth Primary Vital Sign
[ Tue, Dec 13th 2011 ] - Market Wire
China Botanic Announces Development of New Siberian Ginseng Polysaccharide Extract Powder
[ Tue, Dec 13th 2011 ] - Market Wire
Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
Baxter Signs Definitive Agreement to Acquire Synovis
[ Tue, Dec 13th 2011 ] - Market Wire
St. Jude Medical Board of Directors Authorizes Share Repurchase and Fourth Quarter Dividend
[ Tue, Dec 13th 2011 ] - Market Wire
SANUWAVE Technology Shown to Proliferate Adult Stem Cells
[ Tue, Dec 13th 2011 ] - Market Wire
Cubist Announces First Patient Dosed in Pivotal G .. XA-201 for Complicated Intra-Abdominal Infections
[ Tue, Dec 13th 2011 ] - Market Wire
Alnylam Scientists Present New Data on RNAi Therapeutics at 53rd ASH Annual Meeting
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase II evala la ventaja clnica de pom .. con mieloma mltiple con pretratamiento intensivo
[ Tue, Dec 13th 2011 ] - Market Wire
Fase 2-onderzoek evalueert klinisch profijt van p .. j eerder behandelde patinten met multipel myeloom
[ Tue, Dec 13th 2011 ] - Market Wire
Endgltige Daten aus multizentrischer Phase-II-Stu .. binationstherapie von VIDAZA und REVLIMID fr MDS-
[ Tue, Dec 13th 2011 ] - Market Wire
Presentados en ASH los datos finales de un estudi .. evala la combinacin de VIDAZA y REVLIMID en pacie
[ Tue, Dec 13th 2011 ] - Market Wire
Phase-II-Studie von ISTODAX bei Patienten mit rez .. peripheres T-Zell-Lymphom): Prsentation der Teila
[ Tue, Dec 13th 2011 ] - Market Wire
Estudio de Fase II de ISTODAX en pacientes con li .. (PTCL) recurrente o resistente: presentado en ASH
[ Tue, Dec 13th 2011 ] - Market Wire
Fase II onderzoek van ISTODAX bij patinten met re .. len perifeer t-cel lymfoom (PTCL): subanalyse van

Fase II onderzoek van ISTODAX bij patinten met recidief of moeilijk te behandelen perifeer t-cel lymfoom (PTCL): subanalyse van


Published on 2011-12-13 04:45:25 - Market Wire
  Print publication without navigation


BOUDRY, Switzerland--([ ])--Celgene International Srl, een dochteronderneming van Celgene Corporation (Nasdaq:CELG) meldt gegevens van een subanalyse van een Fase II, multicenter, internationaal, open-label onderzoek van ISTODAX (romidepsin) bij moeilijk te behandelen of recidief PTCL volgend op eerdere systemische behandeling. De gegevens werden gepresenteerd door Professor Bertrand Coiffier van het Hospices Civils de Lyon en de Universit Lyon op de 53ste jaarvergadering van de Amerikaanse Vereniging voor Hematologie. Bij 46 procent van de patinten kwam de ziekte voor minstens 90 dagen onder controle. De gemiddelde duur van de respons voor alle patinten die reageerden op de therapie bedroeg 17 maanden. Eendere responsgegevens werden aangetoond bij de meest voorkomende subtypes van PTCL.

Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal welke als enige juridische geldigheid beoogt.

Contributing Sources